Search

Your search keyword '"Schaeverbeke, Thierry"' showing total 7 results
Start Over Author "Schaeverbeke, Thierry" Language undetermined
7 results on '"Schaeverbeke, Thierry"'

1. Effectiveness of vedolizumab for Crohn's disease with spondyloarthritis in fail with two TNF blocking agents

Author

Morel, Jacques, Constantin, Arnaud, Baron, Gabriel, Dernis, Emmanuelle, Flipo, Rene Marc, Rist, Stéphanie, Combe, Bernard, Gottenberg, Jacques Eric, Soubrier, Martin, Dougados, Maxime, Saraux, Alain, Ravaud, Philippe, Sibilia, Jean, Truchetet, Marie-Elise, Dublanc, Stéphanie, Barnetche, Thomas, Mariette, Xavier, Richez, Christophe, Blanco, Patrick, Mahler, Michael, Contin-Bordes, Cécile, Schaeverbeke, Thierry, Banse, Christopher, Armengol-Debeir, Laura, Vittecoq, Olivier, Université de Montpellier (UM), Service de rhumatologie, Centre Hospitalier Le Mans (CH Le Mans), Service de rhumatologie[Lille], Hôpital Roger Salengro [Lille]-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Médecine Interne, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Lapeyronie [Montpellier] (CHU), Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Lymphocytes B, Autoimmunité et Immunothérapies (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-LabEX IGO Immunothérapie Grand Ouest-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service Physiologie, Les Hôpitaux Universitaires de Strasbourg (HUS)-Nouvel Hôpital Civil, Immunology and Allergy, University Hospital and School of Medicine, Université de Bordeaux (UB), Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, CHU Le Kremlin-Bicêtre (Rheumatology Department), Department of Rheumatology, Composantes innées de la réponse immunitaire et différenciation (CIRID), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), INOVA Diagnostics, San Diego, CHU Bordeaux [Bordeaux], UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Physiopathologie et biothérapies des maladies inflammatoires et autoimmunes, Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Hôpital Charles Nicolle [Rouen]-Université de Rouen Normandie (UNIROUEN), and Normandie Université (NU)-Normandie Université (NU)-CHU Rouen

Subjects
030203 arthritis & rheumatology, 0301 basic medicine, medicine.medical_specialty, Crohn's disease, Blocking (radio), business.industry, [SDV]Life Sciences [q-bio], Treatment outcome, Follow up studies, Joint bone, medicine.disease, 3. Good health, Vedolizumab, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Rheumatology, Internal medicine, Physical therapy, medicine, Tumor necrosis factor alpha, business, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, medicine.drug
Abstract

Joint Bone Spine - In Press.Proof corrected by the author Available online since samedi 5 aout 2017

Published
2018

2. Recommendations of the French Society for Rheumatology regarding TNFα antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update

Author

Pham, Thao, Fautrel, Bruno, Dernis, Emmanuelle, Goupille, Philippe, Guillemin, Francis, Le Loët, Xavier, Ravaud, Philippe, Claudepierre, Pascal, Miceli-Richard, Corinne, De Bandt, Michel, Breban, Maxime, Maillefert, Jean-Francis, Masson, Charles, Saraux, Alain, Schaeverbeke, Thierry, Wendling, Daniel, Mariette, Xavier, Combe, Bernard, Renseigné, Non, Service de Rhumatologie [Hôpital de la Conception - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de rhumatologie, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre d'investigation clinique - Epidémiologie clinique [Nancy] (CIC-EC), Centre d'investigation clinique [Nancy] (CIC), Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de rhumatologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Département d'épidémiologie, biostatistique et recherche clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de rhumatologie [CHU Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Service de Rhumatologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], CHU Bordeaux [Bordeaux], Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Service de Rhumatologie [CHU Pitié Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
MESH: Antirheumatic Agents, medicine.medical_specialty, Health Status, MESH: Societies, Medical, MESH: Professional Practice, Arthritis, Severity of Illness Index, MESH: Antibodies, Monoclonal, 03 medical and health sciences, Psoriatic arthritis, 0302 clinical medicine, MESH: Practice Guidelines as Topic, Rheumatology, MESH: Rheumatology, MESH: Severity of Illness Index, Internal medicine, medicine, MESH: Arthritis, Psoriatic, Humans, Spondylitis, Ankylosing, 030212 general & internal medicine, BASDAI, MESH: Health Status, Societies, Medical, Leflunomide, 030203 arthritis & rheumatology, Ankylosing spondylitis, MESH: Humans, Tumor Necrosis Factor-alpha, business.industry, Arthritis, Psoriatic, Antibodies, Monoclonal, Professional Practice, MESH: Spondylitis, Ankylosing, medicine.disease, Infliximab, 3. Good health, Discontinuation, Surgery, MESH: France, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, MESH: Tumor Necrosis Factor-alpha, Antirheumatic Agents, Practice Guidelines as Topic, France, business, medicine.drug
Abstract

International audience; OBJECTIVE: To update French Society for Rheumatology guidelines regarding the use of tumor necrosis factor alpha (TNFalpha) antagonists for treating patients with ankylosing spondylitis (AS) or psoriatic arthritis (PsA). METHODS: We used the method recommended by Shekelle et al. to update the original recommendations: a limited group of experts selected the items that required updating, the relevant literature was critically appraised, and the experts developed new wording for the recommendations, which was then subjected to internal and external validation. As with the original recommendations, three topics were addressed, namely, indications of TNFalpha antagonist therapy, treatment initiation, and treatment adjustment and follow-up. RESULTS: Four criteria should be used to evaluate the indication of TNFalpha antagonist therapy. First, the patient must have a definitive diagnosis of AS or PsA. Thus, patients with AS must meet modified New York criteria or exhibit characteristic involvement of the sacroiliac joints, spine, or peripheral sites documented by radiographs or computed tomography (structural damage) or by magnetic resonance imaging (inflammation). Patients with PsA must meet validated criteria such as the Moll and Wright or CASPAR criteria. The second criterion is active disease for more than 1month, with a BASDAI >or=4 in patients with predominantly axial disease or a tender/swollen joint count >or=3, and with a physician assessment of disease activity of >or=4/10. The third criterion is failure of at least three non-steroidal anti-inflammatory drugs in patients with axial disease or of disease-modifying antirheumatic drug (DMARD) therapy (methotrexate, salazopyrine, or leflunomide) in patients with peripheral disease. Fourth, the patient must be free of contraindications to TNFalpha antagonist therapy. Four recommendations pertain to the initiation of TNFalpha antagonist therapy: a workup should be performed prior to treatment initiation; there is no evidence that one TNFalpha antagonist is more effective than the others, so decisions about drug selection should be shared with the patient and guided by available safety data and the patient's profile; there is no proof that greater effectiveness can be achieved by routinely combining a conventional DMARD; and patients should receive regular standardized follow-up. The last four recommendations deal with adjusting TNFalpha antagonist therapy: the treatment objective is a 2-point or greater improvement in the BASDAI in patients with axial disease and a 30% or greater improvement in the tender/swollen joint counts in patients with peripheral disease; there is no evidence to support the introduction of DMARD therapy in non-responders, who can be switched to another TNFalpha antagonist or, when on infliximab, given higher dosages or more closely spaced injections; patients who fail to tolerate one TNFalpha antagonist can be switched to another TNFalpha antagonist if allowed by the nature of the adverse event; and when a remission is achieved, reduction or discontinuation of concomitant anti-inflammatory therapy should be considered, followed in the event of a prolonged remission by a reduction in the dosage of the TNFalpha antagonist.

Published
2007

3. Reply to the comment of Brinster et al. 'Acquired hemophilia, rheumatoid arthritis, and TNFα antagonists'

Author

Gazal, Steven, Sacré, Karim, Allanore, Yannick, Teruel, Maria, Goodall, Alison, Tohma, Shigeto, Alfredsson, Lars, Okada, Yukinori, Xie, Gang, Constantin, Arnaud, Balsa, Alejandro, Kawasaki, Aya, Nicaise, Pascale, Amos, Christopher, Rodríguez-Rodríguez, Luis, Chiocchia, Gilles, Boileau, Catherine, Zhang, Jinyi, Barnetche, Thomas, Gonzalez-Gay, Miguel, Furukawa, Hiroshi, Cantagrel, Alain, Le Loët, Xavier, Sumida, Takayuki, Hurtado-Nedelec, Margarita, Richez, Christophe, Chollet-Martin, Sylvie, Schaeverbeke, Thierry, Combe, Bernard, Khoryati, Liliane, Coustet, Baptiste, El-Benna, Jammel, Siminovitch, Katherine, Plenge, Robert, Padyukov, Leonid, Martin, Javier, Tsuchiya, Naoyuki, Devauchelle-Pensec, Valérie, Gottenberg, Jacques-Eric, Jousse-Joulin, Sandrine, Berthelot, Jean-Marie, Perdriger, Aleth, Hatron, Pierre Yves, Puéchal, Xavier, Le Guern, Véronique, Sibilia, Jean, Chiche, Laurent, Goëb, Vincent, Larroche, Claire, Fauchais, Anne-Laure, Hayem, Gilles, Morel, Jacques, Zarnitsky, Charles, Dubost, Jean Jacques, Dieudé, Philippe, Pers, Jacques Olivier, Cornec, Divi, Seror, Raphaele, Mariette, Xavier, Nowak, Emmanuel, Saraux, Alain, Banse, Christopher, Vittecoq, Olivier, Levesque, Hervé, Université Paris Diderot - Paris 7 (UPD7), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de rhumatologie [CHU Cochin], CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Spanish National Research Council (CSIC), Department of Cardiovascular Sciences [Leicester], University of Leicester, University of Tsukuba, Centre for Occupational and Environmental Medicine, Stockholm County Council, Broad Institute of MIT and Harvard (BROAD INSTITUTE), Harvard Medical School [Boston] (HMS)-Massachusetts Institute of Technology (MIT)-Massachusetts General Hospital [Boston], University of Toronto, School of Informatics [Edimbourg], University of Edinburgh, University Hospital La Paz, Madrid, Service d'Immunologie, Hôpital Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris (AP-HP)-Assistance Publique-Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-PRES Sorbonne Paris Cité, Dartmouth College [Hanover], Rheumatology Service, Hospital Clínico San Carlos, Physiopathologie et Pharmacologie Clinique de la Douleur (LPPD), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de cardiologie, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 (UPD7), Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Kyushu University [Fukuoka], Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Protéines de défense des réponses immune et inflammatoire : identification, régulation et rôles physiopathologiques, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Université Paris-Sud - Paris 11 (UP11), Service de rhumatologie, CHU Bordeaux [Bordeaux], Hôpital Lapeyronie [Montpellier] (CHU), Service de Rhumatologie, Département Hospitalo-Universitaire (DHU), Merck & Co. Inc, Karolinska Institutet [Stockholm], Institute of Parasitology and Biomedicine (IPB - GRANADA), Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Pontchaillou [Rennes], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Saint-Antoine [APHP], Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Hôpital Européen [Fondation Ambroise Paré - Marseille], Service de rhumatologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Internal Medicine, Paris, Service de Médecine interne A et polyclinique médicale [CHU Limoges], CHU Limoges, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Ambroise Paré, Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Service de Rhumatologie - CH Le Havre, CH Le Havre, Département rhumatologie, CHU Clermont-Ferrand, Service de rhumatologie [Bichat], Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, CHU Cochin [AP-HP], CHU Le Kremlin-Bicêtre (Rheumatology Department), Department of Rheumatology, CIC Brest, Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital de la Cavale Blanche, Institute for Research and Innovation in Biomedicine (IRIB), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Tsukuba = University of Tsukuba, Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de rhumatologie [CHU Rouen], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Lymphocytes B, Autoimmunité et Immunothérapies (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-LabEX IGO Immunothérapie Grand Ouest-Institut Brestois Santé Agro Matière (IBSAM), and Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
musculoskeletal diseases, medicine.medical_specialty, congenital, hereditary, and neonatal diseases and abnormalities, Etiology, MESH: Etanercept/adverse effects, [SDV]Life Sciences [q-bio], education, MESH: Arthritis, Rheumatoid/drug therapy, TNFα antagonists, Hemophilia A, Etanercept, Arthritis, Rheumatoid, Rheumatology, hemic and lymphatic diseases, medicine, Humans, MESH: Hemophilia A/chemically induced, Rheumatoid arthritis, skin and connective tissue diseases, MESH: Humans, business.industry, Biotherapy, MESH: Antirheumatic Agents/adverse effects, Joint bone, medicine.disease, Dermatology, Surgery, Acquired hemophilia, Antirheumatic Agents, [SDV.IMM]Life Sciences [q-bio]/Immunology, Tumor necrosis factor alpha, Female, business, MESH: Female
Abstract

Comment on:- Acquired hemophilia possibly induced by etanercept in a patient with rheumatoid arthritis. [Joint Bone Spine. 2015]- Acquired hemophilia, rheumatoid arthritis, and TNFα antagonists: Comment on the article "Acquired hemophilia possibly induced by etanercept in a patient with rheumatoid arthritis" by Banse et al., Joint Bone Spine 2015;82:200-2. [Joint Bone Spine. 2015]; International audience; Correspondance

Published
2015

4. Prevalence of Gout in the Adult Population of France

Author

Bardin, Thomas, Bouée, Stéphane, Clerson, Pierre, Chales, Gérard, Flipo, René-Marc, Lioté, Frédéric, Perez, Vincent, Poiraud, Thierry, Schaeverbeke, Thierry, Richette, Pascal, Service de rhumatologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Orgamétrie biostatistiques, Service de rhumatologie [Rennes] = Rheumatology [Rennes], CHU Pontchaillou [Rennes], Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Département de Rhumatologie (LILLE - Rhumatologie), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Os et articulations, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service Rhumatologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), CHU Bordeaux [Bordeaux], UFR Médicale, Université Paris Diderot - Paris 7 (UPD7), Fédération de rhumatologie, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Ménarini France, Association Rhumatisme et Travail, Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
Adult, Male, Adolescent, Gout, [SDV]Life Sciences [q-bio], Age Factors, Middle Aged, Young Adult, Cross-Sectional Studies, Sex Factors, Prevalence, Humans, Female, France, Aged
Abstract

International audience; OBJECTIVE: To estimate adult gout prevalence in France. METHODS: We used a previously established phone questionnaire that allowed for classifying patients as gouty or non-gouty by 2 logistic regression models and 1 Classification and Regression Tree (CART) method, the sensitivity and specificity of which were all more than 80%. The full questionnaire was administered by phone to subjects who acknowledged present or past non-traumatic acute pain in a peripheral joint, the others being classified as non-gouty. A random sample of adults residing in France was derived from the national telephone (home and mobile) directory by the quota method and further redressed to match the French population. The target size for the interview survey conducted in March and June 2013 was 10,000 participants. RESULTS: We interviewed 10,026 participants. All three models (2 logistic regression and CART models) converged to an estimated gout prevalence of 0.9%. This was lower than that estimated by self-reporting only (3.7%; 95% CI: 3.3-4.1). The prevalence was higher for males than females and increased with age but did not differ by area of France. CONCLUSION: Gout prevalence in the adult population of France in 2013 was estimated at 0.9%. Studies using self-reporting only might overestimate the prevalence. This article is protected by copyright. All rights reserved

Published
2015

5. Additional file 1: of Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

Author

Bertrand, Anne, Kostine, Marie, Barnetche, Thomas, Marie-Elise Truchetet, and Schaeverbeke, Thierry

Abstract

Figures S5 to S7 Global immune-related adverse events (irAEs) with ipilimumab all dosage, 3 mg/kg, and 10 mg/kg for all grades and high grade. Figures S8 to S27 Organ-specific irAEs (endocrine, skin, gastrointestinal, and hepatic) for ipilimumab all dosage, 3 mg/kg, and 10 mg/kg and Tremelimumab, for all grades and high grade. Figures S28 to S31 Risk ratio of developing irAEs with ipilimumab at 10 mg/kg comparing with 3 mg/kg for organ-specific irAEs (gastrointestinal, skin, endocrine, and hepatic). Table S2 General characteristics of patients receiving anti-CTLA4 antibodies described in case reports. Table S3 Organ-specific irAEs. Table S4 Quality assessment. (DOCX 12329 kb)

Published
2015
Full Text
View/download PDF

6. TNFalpha antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology

Author

Pham, Thao, Guillemin, Francis, Claudepierre, Pascal, Luc, Mathieu, Miceli-Richard, Corinne, Fautrel, Bruno, De Bandt, Michel, Breban, Maxime, Goupille, Philippe, Maillefert, Jean-Francis, Masson, Charles, Saraux, Alain, Schaeverbeke, Thierry, Wendling, Daniel, Mariette, Xavier, Combe, Bernard, Renseigné, Non, Service de Rhumatologie [Hôpital de la Conception - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Centre d'investigation clinique - Epidémiologie clinique [Nancy] (CIC-EC), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service de rhumatologie [CHU Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Service de rhumatologie, Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Rhumatologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Bordeaux [Bordeaux], Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Service de Rhumatologie [CHU Pitié Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
medicine.medical_specialty, Anti-Inflammatory Agents, Disease, 03 medical and health sciences, Psoriatic arthritis, 0302 clinical medicine, Rheumatology, Sulfasalazine, Internal medicine, MESH: Rheumatology, medicine, MESH: Arthritis, Psoriatic, Humans, Spondylitis, Ankylosing, 030212 general & internal medicine, BASDAI, Leflunomide, 030203 arthritis & rheumatology, Ankylosing spondylitis, MESH: Humans, business.industry, Tumor Necrosis Factor-alpha, Arthritis, Psoriatic, medicine.disease, MESH: Spondylitis, Ankylosing, 3. Good health, MESH: France, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, MESH: Anti-Inflammatory Agents, MESH: Tumor Necrosis Factor-alpha, Methotrexate, France, business, medicine.drug
Abstract

International audience; OBJECTIVES: To develop recommendations for TNFalpha antagonist therapy in patients with spondyloarthropathies. METHODS: The Delphi consensus procedure was used to select questions, to which evidence-based answers were sought in the literature. Expert opinion was used when needed to estimate the risks and benefits of TNFalpha antagonists. TNFalpha antagonists exert potent antiinflammatory effects but fail to provide a definitive cure. RESULTS: Recommendations were developed for patients with ankylosing spondylitis (AS) or psoriatic arthritis (PsA). The following criteria for TNFalpha antagonist therapy were selected: definitive diagnosis of AS or PsA, active disease for at least 4 consecutive weeks documented during two physician visits, overall physician's assessment of disease activity>/=4/10 and BASDAI>/=4/10 in axial disease or at least three tender and swollen joints in peripheral disease, failure to respond adequately to at least three nonsteroidal antiinflammatory drugs given in optimal dosages for at least 3 months in axial disease or at least one disease-modifying antirheumatic drug (methotrexate, leflunomide, sulfasalazine) for at least 4 months, with local glucocorticoid injections if appropriate, in peripheral disease. Effectiveness and safety should be evaluated by a rheumatologist. The frequency of monitoring depends on the drug. Lack of effectiveness should be defined as inadequate improvement after 6-12 weeks, with a less than two-point decrease in the BASDAI in axial disease or a less than 30% decrease in the tender and swollen joint counts in peripheral disease. CONCLUSION: These clinical practice recommendations should help rheumatologists in their everyday decisions regarding the use of TNFalpha antagonist therapy in patients with AS or PsA.

Published
2005

7. Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)

Author

Ramiro, Sofia, Landewé, Robert Bm, Van Der Heijde, Désirée, Sepriano, Alexandre, FitzGerald, Oliver, Ostergaard, Mikkel, Homik, Joanne, Elkayam, Ori, Thorne, J Carter, Larche, Margaret, Ferraccioli, Gianfranco, Backhaus, Marina, Boire, Gilles, Combe, Bernard, Schaeverbeke, Thierry, Saraux, Alain, Dougados, Maxime, Rossini, Maurizio, Govoni, Marcello, Sinigaglia, Luigi, Cantagrel, Alain G, Allaart, Cornelia F, Barnabe, Cheryl, Bingham, Clifton O, Tak, Paul P, Van Schaardenburg, Dirkjan, Hammer, Hilde Berner, Dadashova, Rana, Hutchings, Edna, Paschke, Joel, and Maksymowych, Walter P

Subjects
rheumatoid arthritis, Adult, Male, treat-to-target, Clinical Decision-Making, Remission Induction, Blood Sedimentation, Middle Aged, Patient Care Planning, 3. Good health, Arthritis, Rheumatoid, Cohort Studies, remission, C-Reactive Protein, Rheumatoid Factor, Antirheumatic Agents, Humans, Female, Tumor Necrosis Factor Inhibitors, Longitudinal Studies, Aged
Abstract

OBJECTIVES: To investigate whether following a treat-to-target (T2T)-strategy in daily clinical practice leads to more patients with rheumatoid arthritis (RA) meeting the remission target. METHODS: RA patients from 10 countries starting/changing conventional synthetic or biological disease-modifying anti-rheumatic drugs were assessed for disease activity every 3 months for 2 years (RA BIODAM (BIOmarkers of joint DAMage) cohort). Per visit was decided whether a patient was treated according to a T2T-strategy with 44-joint disease activity score (DAS44) remission (DAS44

Catalog

Books, media, physical & digital resources
See catalog results